Web Toolbar by Wibiya
Login | Sign Up AnonymousUser
New to Comunitee?

or Sign Up with Email



JAN 22, 2013 - Yahoo! News

A Must Read - Share

Celgene's Abraxane increases survival in pancreatic cancer

(Reuters) - Celgene Corp said its Abraxane drug helped patients with advanced pancreatic cancer live an average of two months longer than chemotherapy and significantly increased the percentage of those who survived with the disease for up to two years, according to a late-stage study. Based on the results, Celgene said it expects to file applications in the United States and Europe in the first half of this year seeking approval for the use of Abraxane for pancreatic cancer. ...

Tags: Celgene's Abraxane increases survival in pancreatic cancer,  Pancreatic Cancer Latest News